BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6413375)

  • 1. Low-dose 131I fails to hold euthyroidism in Graves' cases.
    Hosp Pract (Off Ed); 1983 Oct; 18(10):40-1. PubMed ID: 6413375
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
    Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
    N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease.
    McCullagh EP; Jelden GL; Rodriguez-Antunez A
    Ohio State Med J; 1976 Sep; 72(9):538-40. PubMed ID: 989600
    [No Abstract]   [Full Text] [Related]  

  • 6. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism.
    Gómez JM; Gómez N; Amat M; Biondo S; Rafecas A; Jaurrieta E; Soler J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):184-91. PubMed ID: 10970941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypothyreosis after I-131 therapy of Graves-Basedow disease].
    Fazakas S; Kiss B; Erdei I; Petrányi G
    Orv Hetil; 1975 Oct; 116(43):2523-6. PubMed ID: 1242529
    [No Abstract]   [Full Text] [Related]  

  • 10. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Surgical treatment of graves' disease: is it still appropriate today? (author's transl)].
    Bürgi H; Lupi GA; Maurer W
    Ther Umsch; 1979 Oct; 36(10):899-903. PubMed ID: 93787
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of nuclear medicine in the management of Graves' disease.
    Freitas JE
    Q J Nucl Med; 1999 Dec; 43(4):297-306. PubMed ID: 10731780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative follow-up of patients with hyperthyroidism treated with 131 or surgery.
    Alizadeh J; Ward JA
    J Med Assoc Ga; 1979 Feb; 68(2):101-4. PubMed ID: 581675
    [No Abstract]   [Full Text] [Related]  

  • 14. [Radioiodine therapy of recurrent hyperthyroidism in patients previously treated for diffuse toxic goiter with subtotal surgery].
    Vestergaard H; Laurberg P
    Ugeskr Laeger; 1993 Aug; 155(31):2403-5. PubMed ID: 8346592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term surveillance of patients treated for Basedow's disease].
    Chavrier B; Berthezene F; Mornex R
    Ann Endocrinol (Paris); 1974; 35(1):72-3. PubMed ID: 4479479
    [No Abstract]   [Full Text] [Related]  

  • 16. [131I-therapy of Basedow's disease and nonimmunogenic hyperthyroidism].
    Hoeschel M; Heinze HG
    Nuklearmedizin; 1984 Jun; 23(3):143-9. PubMed ID: 6548309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
    Watson AB; Brownlie BE; Frampton CM; Turner JG; Rogers TG
    Clin Endocrinol (Oxf); 1988 May; 28(5):487-96. PubMed ID: 3214941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.